Trials / Terminated
TerminatedNCT02258867
Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease Uveitis
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- XOMA (US) LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to assess the efficacy and safety of gevokizumab in treating Behcet's disease uveitis (BDU).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Solution for subcutaneous injection |
| DRUG | Gevokizumab | Solution for subcutaneous injection |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2015-10-01
- Completion
- 2015-11-01
- First posted
- 2014-10-08
- Last updated
- 2015-12-29
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02258867. Inclusion in this directory is not an endorsement.